Evogene Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
EVGN
IL0011050551
Biotechnology & Medical Research
Sales 2024 * | 17M 63.87M | Sales 2025 * | 31.5M 118M | Capitalization | 35.15M 132M |
---|---|---|---|---|---|
Net income 2024 * | -20M -75.14M | Net income 2025 * | -17M -63.87M | EV / Sales 2024 * | 2.07 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.12 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.27% |
Latest transcript on Evogene Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
+48.77% | 41.56B | |
-0.97% | 41.71B | |
+4.36% | 39.74B | |
-14.64% | 25.61B | |
+3.87% | 24.26B | |
-23.35% | 18.55B | |
-1.72% | 11.93B | |
+25.62% | 11.93B | |
+5.32% | 10.91B |